Compare EDIT & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDIT | GUG |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.3M | 462.7M |
| IPO Year | 2016 | 2021 |
| Metric | EDIT | GUG |
|---|---|---|
| Price | $1.63 | $13.58 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $6.10 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 95.8K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,937,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.64 | N/A |
| 52 Week Low | $1.66 | $13.55 |
| 52 Week High | $3.94 | $16.46 |
| Indicator | EDIT | GUG |
|---|---|---|
| Relative Strength Index (RSI) | 29.08 | 36.98 |
| Support Level | N/A | $13.55 |
| Resistance Level | $3.00 | $16.11 |
| Average True Range (ATR) | 0.21 | 0.22 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 1.10 | 5.83 |
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The Fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The Fund represents a single operating segment. Its products are Mutual Funds, Wealth Management SMAS, Institutional SMAS, ETFS, UITS, UCITS, CIT, Closed-End Funds, Private Funds, Rydex Funds, and Variable Insurance Funds.